Surgical Site Infection - Pipeline Insight, 2024

This “Surgical Site Infection - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Surgical Site Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Surgical Site Infection Understanding

Surgical Site Infection: Overview

A surgical site infection is an infection that occurs after surgery in the part of the body where the surgery took place. Surgical site infections can sometimes be superficial infections involving the skin only. Other surgical site infections are more serious and can involve tissues under the skin, organs, or implanted material. CDC provides guidelines and tools to the healthcare community to help end surgical site infections and resources to help the public understand these infections and take measures to safeguard their own health when possible. The symptoms of a surgical site infection typically appear 5 to 7 days post-procedure, however can develop up to 3 weeks after (especially if a prosthesis is inserted). The common clinical features of surgical site infections include: Spreading erythema; localized pain; Pus or discharge from the wound; and Persistent pyrexia.

Surgical Site Infection - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Surgical Site Infection pipeline landscape is provided which includes the disease overview and Surgical Site Infection treatment guidelines. The assessment part of the report embraces, in depth Surgical Site Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Surgical Site Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Surgical Site Infection.
• In the coming years, the Surgical Site Infection market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies and academics that are working to assess challenges and seek opportunities that could influence Surgical Site Infection R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• A detailed portfolio of major pharma players who are involved in fueling the Surgical Site Infection treatment market. Several potential therapies for Surgical Site Infection are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Surgical Site Infection market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Surgical Site Infection) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Surgical Site Infection Emerging Drugs Chapters

This segment of the Surgical Site Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Surgical Site Infection Emerging Drugs

XF-73: Destiny Pharma plc XF-73 is a synthetic dicationic porphyrin derivative with antibacterial activity. XF-73 has confirmed bactericidal activity. It is designated by the International Non-proprietary Name (INN) of exeporfinium chloride by the World Healthcare Organisation (WHO). XF-73 has been tested in vitro against a range of clinically important S. aureus isolates. It is active against methicillin-resistant S. aureus (MRSA), methicillin-sensitive S. aureus (MSSA), hospital associated-MRSA (HA-MRSA) and community-acquired MRSA (CA-MRSA), daptomycin resistant S. aureus, low- and high-level mupirocin-resistant S. aureus, linezolid-resistant MRSA and vancomycin-intermediate S. aureus(VISA).

D-PLEX100: POLYPIDPLEX (Polymer-Lipid Encapsulation matriX) platform is made of alternating layers of polymers and lipids that entrap a therapeutic drug to form a protected reservoir. PLEX-based drug reservoirs enable prolonged delivery of unmodified drugs over periods ranging from days to several months, a rare combination of attributes. The novel D-PLEX100 product candidate delivers a broad-spectrum antibiotic, doxycycline, generating high local concentration over four weeks with minimal systemic exposure

Surgical Site Infection: Therapeutic Assessment

This segment of the report provides insights about the different Surgical Site Infection drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Surgical Site Infection

There are approx. 5+ key companies which are developing the therapies for Surgical Site Infection. The companies which have their Surgical Site Infection drug candidates in the most advanced stage, i.e. phase III include, POLYPID.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Surgical Site Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Surgical Site Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Surgical Site Infection therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Surgical Site Infection drugs.

Surgical Site Infection Report Insights

• Surgical Site Infection Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Surgical Site Infection Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Surgical Site Infection drugs?
• How many Surgical Site Infection drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Surgical Site Infection?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Surgical Site Infection therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Surgical Site Infection and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Destiny Pharma plc
• POLYPID
• Exoxemis
• Covira Surgical, Inc.
• Eupraxia Pharmaceuticals
• Sonoran Biosciences

Key Products

• XF-73
• D-PLEX100
• E-101
• EP-201
• SBG003

This product will be delivered within 1-3 business days.